Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering. Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes. About Gain Therapeutics, Inc. Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can resto ...